These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Shigella human challenge model. Porter CK; Thura N; Ranallo RT; Riddle MS Epidemiol Infect; 2013 Feb; 141(2):223-32. PubMed ID: 22906296 [TBL] [Abstract][Full Text] [Related]
5. Establishment of a Shigella sonnei human challenge model in Thailand. Bodhidatta L; Pitisuttithum P; Chamnanchanant S; Chang KT; Islam D; Bussaratid V; Venkatesan MM; Hale TL; Mason CJ Vaccine; 2012 Nov; 30(49):7040-5. PubMed ID: 23069701 [TBL] [Abstract][Full Text] [Related]
6. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Pitisuttithum P; Islam D; Chamnanchanunt S; Ruamsap N; Khantapura P; Kaewkungwal J; Kittitrakul C; Luvira V; Dhitavat J; Venkatesan MM; Mason CJ; Bodhidatta L Clin Vaccine Immunol; 2016 Jul; 23(7):564-75. PubMed ID: 27146000 [TBL] [Abstract][Full Text] [Related]
7. Phylogenetic and Evolutionary Analysis Reveals the Recent Dominance of Ciprofloxacin-Resistant Shigella sonnei and Local Persistence of S. flexneri Clones in India. Muthuirulandi Sethuvel DP; Mutreja A; Pragasam AK; Vasudevan K; Murugan D; Anandan S; Michael JS; Walia K; Veeraraghavan B mSphere; 2020 Oct; 5(5):. PubMed ID: 33028681 [No Abstract] [Full Text] [Related]
9. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Herrington DA; Van de Verg L; Formal SB; Hale TL; Tall BD; Cryz SJ; Tramont EC; Levine MM Vaccine; 1990 Aug; 8(4):353-7. PubMed ID: 2204243 [TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Oaks EV; Turbyfill KR Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513 [TBL] [Abstract][Full Text] [Related]
11. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Kotloff KL; Winickoff JP; Ivanoff B; Clemens JD; Swerdlow DL; Sansonetti PJ; Adak GK; Levine MM Bull World Health Organ; 1999; 77(8):651-66. PubMed ID: 10516787 [TBL] [Abstract][Full Text] [Related]
12. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease. Levine MM; Gangarosa EJ; Barrow WB; Weiss CF Am J Epidemiol; 1976 Jul; 104(1):88-92. PubMed ID: 779465 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R; Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770 [TBL] [Abstract][Full Text] [Related]
14. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538 [TBL] [Abstract][Full Text] [Related]
15. Developing and utilizing controlled human models of infection. Porter CK; Louis Bourgeois A; Frenck RW; Prouty M; Maier N; Riddle MS Vaccine; 2017 Dec; 35(49 Pt A):6813-6818. PubMed ID: 28583306 [TBL] [Abstract][Full Text] [Related]
16. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Frenck RW; Baqar S; Alexander W; Dickey M; McNeal M; El-Khorazaty J; Baughman H; Hoeper A; Barnoy S; Suvarnapunya AE; Kaminski RW; Venkatesan MM Vaccine; 2018 Aug; 36(32 Pt B):4880-4889. PubMed ID: 30037478 [TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines. Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247 [TBL] [Abstract][Full Text] [Related]
18. Epidemiological characterization of resistance and PCR typing of Shigella flexneri and Shigella sonnei strains isolated from bacillary dysentery cases in Southeast Brazil. Penatti MP; Hollanda LM; Nakazato G; Campos TA; Lancellotti M; Angellini M; Brocchi M; Rocha MM; Dias da Silveira W Braz J Med Biol Res; 2007 Feb; 40(2):249-58. PubMed ID: 17273662 [TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparations. Maggiore L; Yu L; Omasits U; Rossi O; Dougan G; Thomson NR; Saul A; Choudhary JS; Gerke C Int J Med Microbiol; 2016 Feb; 306(2):99-108. PubMed ID: 26746581 [TBL] [Abstract][Full Text] [Related]